An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer-Reference-Cited by-同舟云学术

An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer

Published:2021-12 Issue: Volume: Page:
ISSN:0002-9610
Container-title:The American Journal of Surgery
language:en
Short-container-title:The American Journal of Surgery

Author:

Zhang Chunmeng^ORCID,Wu Ruiqian^ORCID,Smith Lynette M.,Baine Michael,Lin Chi^ORCID,Reames Bradley N.^ORCID

Funder

American Cancer Society

American College of Surgeons

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference26 articles.

1. Locally advanced pancreatic cancer: where should we go from here?;Philip;J Clin Oncol,2011

2. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis;Suker;Lancet Oncol,2016

3. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience;Faris;Oncol,2013

4. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX;Michelakos;Ann Surg,2019

5. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages;Gillen;PLoS Med,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and pathological factors associated with survival in patients with pancreatic cancer who receive adjuvant therapy after neoadjuvant therapy: A retrospective multi-institutional analysis;Surgery;2024-05

2. Perioperative and long-term survival outcomes of pancreatectomy with arterial resection in borderline resectable or locally advanced pancreatic cancer following neoadjuvant therapy: a systematic review and meta-analysis;International Journal of Surgery;2023-09-21

3. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s Perspective;Cancer Control;2023-04

4. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma;Journal of Clinical Medicine;2022-08-19

5. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis;Cancers;2021-08-27